After raising AU$29 million (US$19.44 million) in a series A round, Rage Biotech Pty Ltd. is beginning phase I trials of its ...

Asthma, Chronic Obstructive Pulmonary Disease (COPD), allergy and nasal therapies see sustained growth amid severe to very ...

The approval is based on two placebo-controlled phase 3 studies, which showed mepolizumab significantly reduced the annualised rate of moderate/severe exacerbations and time to first moderate/severe ...

The treatment of chronic obstructive pulmonary disease (COPD) has been guided for decades by robust clinical practice guidelines (CPGs), such as NICE1 and GesEPOC,2 as well as international ...

Medical experts have sounded the alarm over the rising burden of Chronic Obstructive Pulmonary Disease (COPD) in Nigeria and across Africa, urging immediate policy reforms, increased public awareness, ...

Medical experts have raised the alarm over the rising burden of Chronic Obstructive Pulmonary Disease (COPD) in Nigeria and across Africa, calling for urgent policy reforms, increased community ...

Chronic obstructive pulmonary disease (COPD) is among the most common lung diseases in the world. According to the World Health Organization, the lung disease is the fourth leading cause of death ...

Background: Long-acting beta-agonist (LABA) plus long-acting muscarinic antagonist (LAMA) is superior to monotherapy or corticosteroid/LABA in terms of improving lung function, alleviating symptoms ...

Chronic Obstructive Pulmonary Disease, or COPD, is a progressive lung condition that affects millions of people in the United States and around the world. Despite its prevalence, many individuals ...

Chronic obstructive pulmonary disease, or COPD, is often thought of as a condition that only affects longtime smokers. In reality, the disease reaches far beyond that group. Women are ...